The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die.
must have diagnosis of metastatic melanoma liver disease by histological confirmation one measurable untreated or progressed liver lesion less than 50% liver involvement must have ECOG performance status of 0-1 must have adequate renal and bone marrow function as: serum creatinine ≤ 2.0 mg/dl, granulocyte count ≥1000/mm3 and platelet count ≥100,000/mm3 must have adequate liver function as: total bilirubin <1.6 mg/ml and albumin >3.0 g/dl
Exclusion Criteria:
failure to meet any of the inclusion criteria solitary liver metastasis that is amenable to surgical removal previous treatment with isolated hepatic perfusion systemic chemotherapy within 2 weeks of study entry significant shunting to the lung (>20%) as identified on Technetium-99m-macro-aggregated albumin nuclear medicine break-through scan unsuccessful closure of collateral blood flows from the hepatic artery to non-targeted organs such as the GI tract symptomatic liver failure including ascites and hepatic encephalopathy metastasis outside of liver requiring systemic treatment within 3 months untreated brain metastasis main portal vein occlusion or inadequate collateral flow uncontrolled hypertension or congestive heart failure acute myocardial infarction within 6 months medical complications with implication of less than 6 month survival uncontrolled severe bleeding tendency or active GI bleed significant allergic reaction to iodinated contrast previous radiation that includes the liver in the main radiation field pregnant or breast-feeding women biliary obstruction, stent, or prior biliary surgery including sphincterotomy but excluding cholecystectomy children under the age of 18
